Specialty drug spending increased a record 31% in 2014, and we forecast spending increases of 21%-22% each year for the next three years. Specialty medications managed through the pharmacy benefit account for more than 32% of a plan’s total pharmacy spend. By 2019, we anticipate that percentage could increase to nearly half of a plan’s total pharmacy spend.
With these current and forecasted spending growth rates, it is critical for plans to understand the pipeline of specialty medications and create a strategy managing these new, costly therapies.
Recently, Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics, provided a comprehensive overview of the specialty pharmacy landscape at the Academy of Managed Care Pharmacy Nexus Conference in Orlando.
Managed Healthcare Executive published a two-part summary of her presentation, highlighting six noteworthy specialty medication approvals and four key conditions that could be greatly impacted by medications in the pipeline.
comments powered by